Literature DB >> 6226677

Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin.

D L Shungu, V Tutlane, H H Gadebusch.   

Abstract

A seven-center collaborative study was carried out to evaluate the in vitro performance of the 10 micrograms norfloxacin disks on the basis of previously proposed interpretive susceptibility zone standards and quality control parameters. Of 7,858 clinical isolates tested, 93.2, 4.9, and 1.9% fell into the susceptible, moderately susceptible, and resistant groups, respectively. The quality control data based on a total of 1,368 zone diameter measurements compared quite favorably with the proposed performance limits as follows: Escherichia coli ATCC 25922, 28 to 35 mm versus 28 to 36 mm; Staphylococcus aureus ATCC 25923, 21 to 29 mm versus 17 to 29 mm; and Pseudomonas aeruginosa ATCC 27853, 23 to 27 mm versus 22 to 29 mm.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226677      PMCID: PMC270948          DOI: 10.1128/jcm.18.4.988-991.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.

Authors:  H H Gadebusch; D L Shungu; E Weinberg; S K Chung
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

2.  Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1983-06       Impact factor: 2.803

3.  Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715).

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

4.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

5.  In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.

Authors:  M Y Khan; R P Gruninger; S M Nelson; R E Klicker
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

7.  In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.

Authors:  J Downs; V T Andriole; J L Ryan
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

8.  In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

9.  Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.

Authors:  K Hirai; A Ito; Y Abe; S Suzue; T Irikura; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

  9 in total
  1 in total

1.  Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.

Authors:  E J Goldstein; M L Alpert; B P Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.